In the present study, it was found that serum exosomal PD-L1 levels were useful for predicting anti-PD-1 therapies for recurrent NSCLC, and that they tended to be associated with survival in patients with NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.